GEN Exclusives

More »

GEN News Highlights

More »
Oct 23, 2008

LCT to Build Pig-Breeding Facility to Help with the Production of Pocrine Islet Cells

  • Living Cell Technologies (LCT) will develop a pathogen free (DPF) facility to breed its pig herd. The facility will be built in Invercargill, New Zealand, and is scheduled to begin operations in early 2009.

    LCT’s porcine insulin producing cell product, DiabeCell®, is being evaluated in multiple type 1 diabetes clinical studies. “Porcine islet cells of uniform quality are critical to the administration of our clinical trials,” points out Paul Tan, Ph.D., COO at LCT. “We have taken great care to ensure facility compliance with animal welfare guidelines as we pursue a treatment for type 1 diabetes.

    “The new facility is integral to the company's future growth, given the recent approval for the initiation of a Phase I/IIa clinical trial in New Zealand and the expansion of our Russian clinical trial, which commenced in mid-2007 and has yielded positive safety and efficacy data to date.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »